Clinical Trial

The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this study is to understand the role of glucagon signal on glucose metabolism in individuals with and without bariatric surgery. The study is involved with measuring glucose metabolism with glucagon infusion and glucagon receptor blockade. We use an investigational drug called REMD 477. "Investigational" means that the has not yet been approved by the U.S. Food \& Drug Administration (FDA). REMD-477 is a monoclonal antibody (an antibody made by cloning a unique white blood cell) that blocks the effect of glucagon.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-10-01; most recent amendment 2026-05-08.
Status change: Not Yet Recruiting → Recruiting 2026-03-09
Trial Details
NCT Number NCT07212868
Lead Sponsor The University of Texas Health Science Center at San Antonio
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions Non-Diabetic
Enrollment 150 participants
Start Date 2026-02-25
Primary Completion 2030-05-01 (estimated)
Study Completion 2030-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-11